glp-1 agonist or antagonist Glucagon-like peptide-1 The Impact of GLP-1 Receptor

The percentage of subjects achieving weight loss (liraglutide 78% versus exenatide 76%) and overall weight loss (liraglutide 3.24 kg versus exenatide 2.87 kg, p = 0.22) was similar between groups

At the same time, these medications cross the blood-brain barrier and directly signal satiety at the hypothalamus

For example, GLP-1As frequently display immunomodulatory properties, which appears to be noteworthy, since chronic inflammatory processes in the brain are often associated with a depressive mood in patients

News Tips Got a confidential news tip

The TAME (Targeting Aging with Metformin) trial is investigating metformin specifically for anti-aging purposes